Phenixfin Corporation · NASDAQ:PFX
Phenixfin — Medley Capital — Q1 FY2013 Earnings Presentation
11 slides from Phenixfin's earnings presentation, February 2013
Slide 1: Quarter Ended December 31, 2012 Investor Presentation
Quarter Ended December 31, 2012 Investor Presentation
Slide 2: Important Notice
Important Notice This presentation contains “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Actual outcomes and results could differ materially from those suggested by this presentation du
Slide 3: Financial & Portfolio Highlights
Financial & Portfolio Highlights Financial Highlights Q1-13 Q4-12 Q3-12 Q2-12 Q1-12 Net investment income per share $ 0.39 $ 0.36 $ 0.36 $ 0.31 $ 0.28 Net realized g gains ((losses)) 0.01 ((0.01)) - - - Net unrealized gains (losses) (0.01) 0.02 (0.08) 0.03 (0.03) Net income per share 0.39 0.37 0.28
Slide 4: Select Financial & Portfolio Information
Select Financial & Portfolio Information As of and for the Three Months Ended (dollars in millions, except per share data) 12/31/2012 9/30/2012 6/30/2012 3/31/2012 12/31/2011 Net investment income per share - basic & diluted $ 0.39 $ 0.36 $ 0.36 $ 0.31 $ 0.28 Net realized and unrealized gains per sh
Slide 5: Balance Sheet
Balance Sheet (dollars in thousands, except per share data) 12/31/2012 9/30/2012 6/30/2012 3/31/2012 12/31/2011 ASSETS (Unaudited) (Audited) (Unaudited) (Unaudited) (Unaudited) Investments at fair value Non-control/non-affiliate investments $ 512,261 $ 393,741 $ 355,035 $ 260,364 $ 198,239 Affiliate
Slide 6: Portfolio by Issuer as of December 31, 2012
Portfolio by Issuer as of December 31, 2012 1 RCS Management Corporation Harrison Gypsum LLC Water Capital USA Inc. Calloway Laboratories, Inc. Cenegenics LLC U.S. Well Services, LLC 1% 1% 1% 0.3% 1% 1% 5% 1% 1% Strike Holdings LLC Physicians Care Alliance LLC 1% 5% 1% Aurora Flight Sciences Corpora
Slide 7: Investment Portfolio as of December 31, 2012
Investment Portfolio as of December 31, 2012 1 Asset Class Industry 1% 2% 1% 0.3% 0.3% 2% 11% 0.7% 2% 2% 2% 2% 2% 9% 2% 3% 34% 3% 9% 5% 5% 65% 8% 6% 8% 7% 7% Healthcare, Education and Childcare Personal and Nondurable Consumer Products (Manufacturing Only) Senior Secured 1st Lien Senior Secured 2nd
Slide 8: Performance Overview
Performance Overview Consistent quarterly dividend ($0.36 for quarter ending 12/31/12) Diversified portfolio with no assets on non non-accrual accrual and a weighted average loan loan-to-value to value (through MCC’s debt) of 55.5% 14.0% portfolio yield as of 12/31/121 FY Q1 2013 gross inves
Slide 9: Performance Since IPO
Performance Since IPO Dividend Growth Portfolio Growth $0.40 $600.0 $0.35 $500.0 $0.30 $400.0 $0.25 ($ millions) $0.20 $300.0 $0.36 $ $0.36 $ $0.36 $ $521 $0.15 $0.31 $0.28 $200.0 $402 $0.25 $363 $0.10 $0.21 $306 $0.16 $249 $100.0 $199 $ $0.05 $145 $105 $85 $0.00 $0.0 Quarterly Dividend Declared Per
Slide 10: Transaction & Backlog Summary
Transaction & Backlog Summary 1 $Amount 2 Deal Sector Security Fixed/Floating Tenor Yield (in millions) Closed in Q1 FY13 Calloway Laboratories, Inc. Healthcare, Education and Childcare Senior - 1st lien $1.7 Fixed 1.8 years 14.1% RCS Management Corporation Diversified/Conglomerate Service Senior -
Slide 11: Corporate Information
Corporate Information Board of Directors Corporate Officers Research Coverage Corporate Counsel BROOK TAUBE BROOK TAUBE BB&T CAPITAL MARKETS SUTHERLAND ASBIL & BRENNAN Chairman & Chief Executive Officer Chairman & Chief Executive Officer Vernon Plack - (804)-780-3257 LLP Washington, DC ANDREW FENTRE